Lescarden Inc.
Not enough financial coverage to compute a composite score for LCAR. This is typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available data still render below.
Companywww.lescarden.com
Lescarden Inc. researches, tests, develops, and sells medications for the control and cure of various diseases in the United States, Europe, and South Korea. Its lead product is Catrix Wound Dressing for the management of chronic lesions and burns, as well as for non-healing wounds, including decubitus ulcers, venous stasis ulcers, and diabetic ulcers.
- CEO
- William E. Luther
- IPO
- 1999
- Employees
- 1
- HQ
- New York City, NY, US
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -0.72
- Avg Volume
- 0
Get TickerSpark's AI analysis on LCAR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our LCAR Coverage
We haven't published any research on LCAR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LCAR Report →